These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 23142648)

  • 21. Vitamin D analogs as therapeutic agents: a clinical study update.
    Wu-Wong JR; Tian J; Goltzman D
    Curr Opin Investig Drugs; 2004 Mar; 5(3):320-6. PubMed ID: 15083599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitive measurement of serum 1α,25-dihydroxyvitamin D by liquid chromatography/tandem mass spectrometry after removing interference with immunoaffinity extraction.
    Yuan C; Kosewick J; He X; Kozak M; Wang S
    Rapid Commun Mass Spectrom; 2011 May; 25(9):1241-9. PubMed ID: 21488122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Benador N; Goldstein SL; Paredes A; Melnick JZ; Mattingly S; Amdahl M; Williams LA; Salusky IB
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection.
    Duplancic D; Cesarik M; Poljak NK; Radman M; Kovacic V; Radic J; Rogosic V
    Clin Interv Aging; 2013; 8():149-56. PubMed ID: 23430986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Standardization of vitamin D assays: art or science?
    Fraser WD
    Ann Clin Biochem; 2009 Jan; 46(Pt 1):3-4. PubMed ID: 19103954
    [No Abstract]   [Full Text] [Related]  

  • 26. Cholecalciferol, not ergocalciferol, should be used for vitamin D supplementation.
    Grant WB
    Age Ageing; 2006 Nov; 35(6):645; author reply 645. PubMed ID: 16982666
    [No Abstract]   [Full Text] [Related]  

  • 27. Severe hyperparathyroidism despite paricalcitol therapy: one-year follow-up.
    Shuja SB; Raja RM
    Adv Perit Dial; 2003; 19():231-5. PubMed ID: 14763069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of vitamin d receptor activators in cardio-renal syndromes.
    Cozzolino M; Bruschetta E; Stucchi A; Ronco C; Cusi D
    Semin Nephrol; 2012 Jan; 32(1):63-9. PubMed ID: 22365164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vascular calcification in chronic kidney disease: new developments in drug therapy.
    Huybers S; Bindels RJ
    Kidney Int; 2007 Sep; 72(6):663-5. PubMed ID: 17805315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitation of 25-OH-vitamin D (25OHD) using liquid tandem mass spectrometry (LC-MS-MS).
    Singh RJ
    Methods Mol Biol; 2010; 603():509-17. PubMed ID: 20077103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The When, What & How of Measuring Vitamin D Metabolism in Clinical Medicine.
    Dirks NF; Ackermans MT; Lips P; de Jongh RT; Vervloet MG; de Jonge R; Heijboer AC
    Nutrients; 2018 Apr; 10(4):. PubMed ID: 29652819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.
    Kovesdy CP; Lu JL; Malakauskas SM; Andress DL; Kalantar-Zadeh K; Ahmadzadeh S
    Am J Kidney Dis; 2012 Jan; 59(1):58-66. PubMed ID: 21885174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perspectives on vitamin D therapy in chronic kidney disease.
    Karalis M
    Nephrol News Issues; 2008 Jul; 22(8):37, 39. PubMed ID: 18711881
    [No Abstract]   [Full Text] [Related]  

  • 34. The D-lemia for preventing secondary hyperparathyroidism in chronic kidney disease.
    Holick MF
    Endocr Pract; 2008; 14(1):6-9. PubMed ID: 18238735
    [No Abstract]   [Full Text] [Related]  

  • 35. Paricalcitol in the treatment of MHD with secondary hyperparathyroidism and bone pain.
    Chen J; Cai L; Wen X; Xie X; Ou S
    Int Urol Nephrol; 2023 May; 55(5):1385-1388. PubMed ID: 36445655
    [No Abstract]   [Full Text] [Related]  

  • 36. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.
    Fernström A; Giæver J; Granroth B; Hylander B; Jensen G; Christensson A; Wikström B; Weiss L; Wrege U; Jacobson SH
    Scand J Urol Nephrol; 2011 Apr; 45(3):196-205. PubMed ID: 21366390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paricalcitol as compared with calcitriol in patients undergoing hemodialysis.
    Drüeke TB; McCarron DA
    N Engl J Med; 2003 Jul; 349(5):496-9. PubMed ID: 12890849
    [No Abstract]   [Full Text] [Related]  

  • 38. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
    Wu-Wong JR; Nakane M; Traylor L; Ruan X; Kroeger PE; Tian J
    Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paricalcitol for reduction of albuminuria in diabetes.
    Delanaye P; Mariat C; Krzesinski JM; Cavalier E
    Lancet; 2011 Feb; 377(9766):635, author reply 636-7. PubMed ID: 21334526
    [No Abstract]   [Full Text] [Related]  

  • 40. Paricalcitol for reduction of albuminuria in diabetes.
    Ortiz A; Sanchez Niño MD; Rojas J; Egido J
    Lancet; 2011 Feb; 377(9766):635-6, author reply 636-7. PubMed ID: 21334525
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.